Unlocking The Potential of ACKR4: A Potential Drug Target and Biomarker

Target Name: ACKR4

NCBI ID: G51554

ACKR4

Unlocking The Potential of ACKR4: A Potential Drug Target and Biomarker

The acyl-coenzyme A (ACKR4) protein is a member of the chemokine receptor-like protein (CCR) family, which is a subgroup of the superfamily of cytoskeletal proteins known as the coiled-coil adapter proteins.ACKR4 is a 22kDa protein that is expressed in various tissues and cells, including the brain, pancreas, and gastrointestinal tract. Its function is not well understood, but it is thought to play a role in the regulation of cellular processes such as cell adhesion, migration, and signaling pathways.

ACKR4 is characterized by a unique structural feature, a long N-terminal cc motif, which is composed of 14 amino acids. This motif is present in multiple species, including humans, and is thought to be involved in protein-protein interactions. In addition , ACKR4 has a unique fold, which is characterized by a distinct N-terminal domain and a unique C-terminal region that contains a putative G protein-coupled receptor (GPCR) domain.

ACKR4 is a protein that has potential as a drug target or biomarker. Its unique structure and function make it an attractive target for researchers to study and potentially exploit for various biological processes.

Drug Target Potential

ACKR4 has been identified as a potential drug target due to its unique structure and function. The N-terminal cc motif and the GPCR domain suggest that ACKR4 may be a GPCR-interactive protein, which means that it could be a good candidate for small molecule inhibitors. Additionally, the protein's unique fold and its expression in various tissues suggest that it may be a good candidate for monoclonal antibodies.

Biomarker Potential

ACKR4 has also been identified as a potential biomarker for certain diseases. Its unique structure and function make it a potential target for diagnostic tests. For example, the N-terminal cc motif may be used as a target for affinity purification assays, which could be used to identify potential diagnostic biomarkers for the protein. Additionally, the protein's unique fold and its expression in various tissues suggest that it may be a good candidate for imaging agents, such as small molecule probes or radioactive tracers.

Conclusion

ACKR4 is a unique and highly conserved protein that has potential as a drug target or biomarker. Its unique structure and function make it an attractive target for small molecule inhibitors and diagnostic tests. Further research is needed to fully understand its function and potential as a drug and biomarker.

Protein Name: Atypical Chemokine Receptor 4

Functions: Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CCL2, CCL8, CCL13, CCL19, CCL21 and CCL25. Chemokine-binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization. Plays an important role in controlling the migration of immune and cancer cells that express chemokine receptors CCR7 and CCR9, by reducing the availability of CCL19, CCL21, and CCL25 through internalization. Negatively regulates CXCR3-induced chemotaxis. Regulates T-cell development in the thymus

The "ACKR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACKR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets